Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita
Developmental Medicine & Child Neurology · 2025
DOI: 10.1111/dmcn.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, 2025. Verfasst von Ahlam Zidan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Arthrogryposis, Psychometrics, Outcome Assessment, Health Care, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Islamic Developmental Bank (IsDB), Shriners Hospitals for Children, Fonds de Recherche du Québec - Santé.
Themen: Mobilisation, Kinderkrankenpflege
Abstract (Originalsprache)
Aim
To establish the construct validity, agreement, and minimal important difference (MID) of widely used mobility measures in arthrogryposis multiplex congenita (AMC).
Method
Participants ( n = 248, 126 males, mean age 10 years 10 months, standard deviation 3 years 11 months) with AMC were assessed using the Functional Mobility Scale (FMS), Gillette Functional Assessment Questionnaire (FAQ), Functional Independence Measure for Children (WeeFIM), and Patient‐Reported Outcomes Measurement Information System (PROMIS). Convergent and discriminant validity were evaluated using Spearman's rank correlations, while known‐groups validity was examined using analysis of variance. Cohen's kappa and distribution‐based methods were used to estimate agreement and MIDs respectively.
Results
Robust convergent ( ρ = 0.66–0.82, 95% confidence interval [CI] 0.54–0.86) and discriminant ( ρ = 0.06–0.31, 95% CI −0.11 to 0.43) validity were found for all four mobility measures. Known‐groups validity was supported by significant mean differences across AMC subtypes (amyoplasia, distal arthrogryposis, central nervous system/syndromic; p < 0.001). The measures also showed weak to good agreement in classifying mobility. A difference of one and two levels on the FMS and FAQ respectively, was found to be minimally important. For the PROMIS and WeeFIM, estimated MID values were 3.19 to 4.34 and 14.24 respectively.
Interpretation
The robust construct validity, agreement, and MIDs provide clinicians and researchers with evidence‐based benchmarks for assessing mobility in children with AMC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Shriners Hospitals for Children, Montreal, Quebec, Canada.
- JSS Medical Research, Montreal, Quebec, Canada.
ORCID-Profile: Ahlam Zidan, Emmanouil Rampakakis, Frank Rauch, Noémi Dahan-Oliel
Förderung
- Islamic Developmental Bank (IsDB)
- Shriners Hospitals for Children
- Fonds de Recherche du Québec - Santé
- Centre for Interdisciplinary Research in Rehabilitation
- Faculty of Medicine, McGill University
- American Society for Bone and Mineral Research
Zitieren
APA
Zidan, A., Snider, L., Rampakakis, E., Hamdy, R., Rauch, F., & Dahan-Oliel, N. (2025). Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.70036
Vancouver
Zidan A, Snider L, Rampakakis E, Hamdy R, Rauch F, Dahan-Oliel N. Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita. Developmental Medicine & Child Neurology. 2025. doi:10.1111/dmcn.70036
BibTeX
@article{Zidan2025,
author = {Zidan, Ahlam and Snider, Laurie and Rampakakis, Emmanouil and Hamdy, Reggie and Rauch, Frank and Dahan-Oliel, Noémi},
title = {Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita},
journal = {Developmental Medicine & Child Neurology},
year = {2025},
doi = {10.1111/dmcn.70036}
}
EUVIMED